

Claims

1. A method of improving photodynamic therapy (PDT) mediated treatment of choroidal neovascularity in a subject comprising

providing, at a frequency of at least about every 45 days during at least a period of three months following an initial PDT treatment, additional PDT treatments to said subject after evaluations for neovascular leakage.
2. The method of claim 1 wherein said frequency is of about every 30 days and the period is for six months following an initial PDT treatment.
3. A method of improving photodynamic therapy (PDT) mediated treatment of choroidal neovascularity in a subject comprising providing, at during a period of about six months following an initial PDT treatment, at least two additional PDT treatments to said subject after evaluations for neovascular leakage.
4. The method of claim 3 wherein said at least two additional PDT treatments are provided at about 45 days and about 90 days following said initial PDT treatment.
5. The method of claim 3 wherein a total of three additional PDT treatments are provided at about 45 days, at about 90 days, and at about 135 days following said initial PDT treatment.
6. The method of claim 3 wherein a total of three additional PDT treatments are provided at about 45 days, at about 90 days, and at about 135 days following said initial PDT treatment.
7. The method of claim 1 or 3, wherein the CNV is in a subject afflicted or diagnosed with age-related macular degeneration (AMD).
8. The method of claim 7, wherein the AMD is the “wet” form.
9. The method of claim 1 or 3, wherein said additional PDT treatments comprise the administration of a photosensitizer (PS).

10. The method of claim 9, wherein the PS is administered at a concentration ranging between about 2 to 8 mg/m² (PS/body surface area of subject).
11. The method of claim 10, wherein the PS is administered at a concentration of 6 mg/m².
12. The method of claim 9, wherein the PS is a green porphyrin.
13. The method of claim 12, wherein the green porphyrin is selected from BPD-DA, BPD-DB, BPD-MA, BPD-MB, EA6, and B3.
14. The method of claim 13, wherein the green porphyrin is BPD-MA.
15. The method of claim 12, wherein the PS is coupled to a specific binding ligand.
16. The method of claim 9, wherein the PS is formulated with a carrier.
17. The method of claim 16, wherein the formulation is selected from the group consisting of a liposome, emulsion, or aqueous solution.
18. The method of claim 1 or 3, wherein said additional PDT treatments comprise irradiation with electromagnetic radiation containing wavelengths in the visible light spectra.
19. The method of claim 18, wherein the irradiation provides between 12.5 J/cm² and 100 J/cm².
20. The method of claim 18, wherein said irradiating occurs between 5 to 30 minutes after administration of a photosensitizer.